Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018 On 16thDecember 2014
Summary The industry analysis specialist, has released its new report, “Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-cancer-vaccines-pipeline-assessment-and-market-forecasts-135232 GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006–2010. During 2010–2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market. The cancer vaccines therapeutic market is expected to show high growth in the forecast period to 2018 due to the expected launch of first-in-class therapeutic cancer vaccines. Presently, there is only one therapeutic cancer vaccine, Provenge, which is a dendritic cell vaccine for advanced prostate cancer patients. Provenge received approval in April 2010 and is presently available only in the US. Dendreon is expecting to file Provenge in Europe in early 2012 and is expected to be launched on the market by mid-2013, which will help drive the therapeutic cancer vaccine market during the forecast period. The expected launch of first-in-class vaccines for different types of cancer during the forecast period to 2018 is expected to drive the cancer vaccines therapeutics market. These drugs include: Allovectin-7 for Melanoma BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma in Europe and the US, Oncovex for melanoma Stimuvax (BLP25 liposome vaccine) for unresectable stage III NSCLC (non-small cell lung cancer). Due to the launch of first-in-class vaccines during the forecast period the therapeutic cancer Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
vaccines market is expected to show high growth.
Scope The report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)Based Vaccine, heated-killed yeast-based vaccine etc. - Analysis of the current and future competition in the seven key countries cancer vaccines market. Key market players covered are Merck, NovaRx Corporation, NewLink Genetics Corporation, Bavarian Nordic, immatics biotechnologies GmbH, Oxford BioMedica, Biovex, Vaccinogen, Biovest International, Vaccinogen and GlaxoSmithKline. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the cancer vaccines market. - Analysis of key recent licensing and partnership agreements in cancer vaccines market.
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Develop business strategies by understanding the trends shaping and driving the global cancer vaccines market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global cancer vaccines market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global cancer vaccines market landscape? – Identify, understand and capitalize.
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Cancer Vaccines - Introduction 2.1 Overview Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2.2 Epidemiology of Various Cancers 2.2.1 Cancer Incidence and Mortality in the US 2.2.2 Cancer Incidence and Mortality in Europe (EU5) 2.2.3 Cancer Incidence and Mortality in Japan. 2.3 Cancer Vaccines 2.3.1 Overview 2.4 Prophylactic Cancer Vaccines 2.4.1 Gardasil (Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant) 2.4.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant) 2.4.3 Cervical Cancer: An Introduction 2.5 Therapeutic Cancer Vaccines 2.5.1 Provenge 2.5.2 Prostate Cancer: An Introduction 2.5.3 Metastatic Prostate Cancer 2.6 Future of Cancer Vaccines 2.6.1 Drawbacks of Available Cancer Therapies 2.6.2 Benefits of the Upcoming Cancer Vaccines 2.7 GlobalData Pipeline Report Guidance 3 Cancer Vaccines - Market Characterization 3.1 Cancer Vaccines Market Size (2005-2010) - Global 3.2 Cancer Vaccines Market Forecast (2010-2018) - Global 3.3 Cancer Vaccines Market Size (2006-2010) - The US 3.4 Cancer Vaccines Market Forecast (2010-2018) - The US 3.5 Cancer Vaccines Market Size (2005-2010) - France 3.6 Cancer Vaccines Market Forecast (2010-2018) - France 3.7 Cancer Vaccines Market Size (2005-2010) - Germany 3.8 Cancer Vaccines Market Forecast (2010-2018) - Germany 3.9 Cancer Vaccines Market Size (2005-2010) - Italy 3.10 Cancer Vaccines Market Forecast (2010-2018) - Italy 3.11 Cancer Vaccines Market Size (2005-2010) - Spain 3.12 Cancer Vaccines Market Forecast (2010-2018) - Spain 3.13 Cancer Vaccines Market Size (2005-2010) - The UK 3.14 Cancer Vaccines Market Forecast (2010-2018) - The UK 3.15 Cancer Vaccines Market Size (2006-2010) - Japan 3.16 Cancer Vaccines Market Forecast (2010-2018) - Japan 3.17 Drivers and Barriers for the Cancer Vaccines Market 3.17.1 Drivers for the Cancer Vaccines Market 3.17.2 Barriers for the Cancer Vaccines Market Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
3.18 Opportunity and Unmet Need Analysis 3.19 Key Takeaway 4 Cancer Vaccines - Competitive Assessment 4.1 Overview 4.1.1 Strategic Competitor Assessment 4.2 Product Profiles for the Major Marketed Products in the Cancer Vaccines Therapeutics Market 4.2.1 Gardasil (HPV Quadrivalent (Type 6, 11, 16 and 18) Vaccine, Recombinant) 4.2.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant) 4.2.3 Provenge (sipuleucel-T) 4.3 Key Takeaway 5 Cancer Vaccines - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.3 Cancer Vaccines Pipeline - Pipeline by Phases of Development 5.3.1 Prophylactic Cancer Vaccines - Phase III Pipeline 5.3.2 Prophylactic Cancer Vaccines - Phase II Pipeline 5.3.3 Prophylactic Cancer Vaccines - Phase I Pipeline 5.3.4 Prophylactic Cancer Vaccines - Preclinical Pipeline 5.3.5 Therapeutics Cancer Vaccines- Phase III Pipeline 5.3.6 Therapeutics Cancer Vaccines - Phase II/III Pipeline 5.3.7 Therapeutics Cancer Vaccines - Phase II Pipeline 5.3.8 Therapeutics Cancer Vaccines - Phase I/II Pipeline 5.3.9 Therapeutics Cancer Vaccines- Phase I Pipeline 5.3.10 Therapeutic Cancer Vaccines Market - Preclinical Pipeline 5.3.11 Technology Trends Analytic Framework 5.4 Cancer Vaccines Market - Pipeline by Vaccine Type 5.5 Cancer Vaccines - Promising Prophylactic Vaccines under Clinical Development 5.6 Profile of Promising Vaccines Under Clinical Development (Prophylactic Cancer Vaccine) 5.6.1 V503 5.7 Cancer Vaccines - Promising Therapeutic Vaccines under Clinical Development 5.8 Vaccines Profiles of Promising Vaccines Under Clinical Development (Therapeutic Cancer Vaccines) 5.8.1 Stimuvax 5.8.2 OncoVAX 5.8.3 OncoVEX (GM-CSF) 5.8.4 Lucanix (belagenpumatucel-L) 5.8.5 Trovax 5.8.6 HyperAcute Pancreas Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.8.7 Allovectin-7 5.8.8 IMA901 5.8.9 BiovaxID 5.8.10 MAGE-A3 ASCI 5.8.11 GV1001 5.9 Key Takeaway 6 Cancer Vaccines - Clinical Trials Mapping 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 6.2 Clinical Trials by Phase 6.3 Clinical Trials by Trial Status 6.4 Prominent Sponsors 6.5 Top Companies Participating in Cancer Vaccines Clinical Trials 7 Cancer Vaccines - Strategic Assessment 7.1 Key Events Impacting the Future Market 7.2 Cancer Vaccines: Implications for Future Market Competition 8 Cancer Vaccines - Future Players 8.1 Introduction 8.2 Company Profiles 8.2.1 Merck & Co., Inc. (Merck). 8.2.2 Vical Incorporated 8.2.3 Vaccinogen 8.2.4 Newlink Genetics Corporation 8.2.5 Biovest International (Subsidiary of Accentual Biopharmaceuticals, Inc.) 8.2.6 Oxford Biomedica 8.2.7 Immatics biotechnologies GmbH 8.2.8 NovaRx Corporation 8.2.9 Oncothyreon 8.2.10 Other Companies in the Cancer Vaccines Market 9 Cancer Vaccines - Licensing and Partnership Deals 10 Cancer Vaccines - Appendix 10.1 Market Definitions 10.2 Abbreviations 10.3 Methodology 10.3.1 Coverage 10.3.2 Secondary Research 10.3.3 Forecasting 10.3.4 Primary Research 10.3.5 Expert Panel Validation 10.4 Contact Us Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.5 Disclaimer 10.6 Bibliography
List Of Tables Table1: Cancer Incidence and Mortality in the US, 2011 Table 2: Cancer Incidence and Mortality in Europe (EU5), 2010 Table 3: Cancer Incidence and Mortality in Japan, 2010 Table 4: Difference Between Autologous and Allogenic Tumor Cell Vaccines. Table 5: Cancer Vaccines Market, Global, Revenue ($m), 2006-2010 Table 6: Cancer Vaccines Market, Global, Forecast, Revenue ($m), 2010-2018 Table 7: Cancer Vaccines Market, The US, Revenue ($m), 2006-2010 Table 8: Cancer Vaccines Market, The US, Forecasts, Revenue ($m), 2010-2018 Table 9: Cancer Vaccines Market, France, Revenue ($m), 2006-2010 Table 10: Cancer Vaccines Market, France, Forecasts, Revenue ($m), 2010-2018 Table 11: Cancer Vaccines Market, Germany, Revenue ($m), 2006-2010 Table 12: Cancer Vaccines Market, Germany, Forecasts, Revenue ($m), 2010-2018 Table 13: Cancer Vaccines Market, Italy, Revenue ($m), 2006-2010 Table 14: Cancer Vaccines Market, Italy, Forecasts, Revenue ($m), 2010-2018 Table 15: Cancer Vaccines Market, Spain, Revenue ($m), 2006-2010 Table 16: Cancer Vaccines Market, Spain, Forecast Revenue ($m), 2010-2018 Table 17: Cancer Vaccines Market, The UK, Revenue ($m), 2006-2010 Table 18: Cancer Vaccines Market, The UK, Forecasts ($m), 2010-2018 Table 19: Cancer Vaccines Market, Japan, Forecasts ($m), 2010-2018 Table 20: Gardasil Approvals and Fillings Table 21: Prophylactic Cancer Vaccines- Phase III Pipeline, 2011 Table 22: Prophylactic Cancer Vaccines- Phase II Pipeline, 2011 Table 23: Prophylactic Cancer Vaccines- Phase I Pipeline, 2011 Table 24: Prophylactic Cancer Vaccines-Preclinical Pipeline, 2011 Table 25: Therapeutic Cancer Vaccines- Phase III Pipeline, 2011 Table 26: Therapeutic Cancer Vaccines- Phase II/III Pipeline, 2011 Table 27: Therapeutic Cancer Vaccines- Phase II Pipeline, 2011 Table 28: Therapeutic Cancer Vaccines- Phase I/II Pipeline, 2011 Table 29: Therapeutic Cancer Vaccines- Phase I Pipeline, 2011 Table 30: Therapeutic Cancer Vaccines- Preclinical Pipeline, 2011 Table 31: Prophylactic Cancer Vaccines -Promising Vaccines Under Clinical Development, 2011 Table 32: Therapeutic Cancer Vaccines -Promising Vaccines Under Clinical Development, 2011 Table 33: Cancer Vaccines - Clinical Trials by Country, 2011 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 34: Cancer Vaccines - Clinical Trials by Phase, 2011 Table 35: Cancer Vaccines - Clinical Trials by Status, 2011 Table 36: Cancer Vaccines - Prominent Sponsors, 2011 Table 37: Cancer Vaccines - Top Companies Participating in Therapeutics Clinical Trials, 2011 Table 38: Vical- Cancer vaccines, Pipeline, 2011 Table 39: Vical- Cancer vaccines, Pipeline, 2011 Table 40: Vaccinogen- Cancer vaccines Pipeline, 2011 Table 41: Newlink Genetics Corporation, Cancer Vaccines Pipeline, 2011 Table 42: Biovest International, Cancer vaccines Pipeline, 2011 Table 43: Oxford BioMedica, Pipeline, 2011 Table 44: Immatics biotechnologies , Cancer Vaccines Pipeline, 2011 Table 45: NovaRx Corporation,Cancer Vaccines Pipeline, 2011 Table 46: Oncothyreon, Cancer Vaccines Pipeline, 2011 Table 47: Cancer Vaccines Market - Future Players Table 48: Cancer Vaccines, Global, Deals
List Of Figures Figure 1: Mechanism of Action of Tumor Cell Vaccine Figure 2: Immunity Induction Pathway by DNA Vaccines. Figure 3: Manner in which Therapeutic Cancer Vaccines are Given in Clinics Figure 4: Cancer Vaccines Market, Global, Revenue ($m), 2006-2010 Figure 5: Prophylactic Cancer Vaccines Market, Global, Forecast ($m), 2010-2018 Figure 6: Therapeutic Cancer Vaccines Market, Global, Forecast ($m), 2010-2018 Figure 7: Cancer Vaccines Market, The US, Revenue ($m), 2006-2010 Figure 8: Prophylactic Cancer Vaccines Market, The US, Forecast ($m), 2010-2018 Figure 9: Therapeutic Cancer Vaccines Market, The US, Forecast ($m), 2010-2018 Figure 10: Cancer Vaccines Market, France, Revenue ($m), 2006-2010 Figure 11: Prophylactic Cancer Vaccines Market, France, Forecast ($m), 2010-2018 Figure 12: Therapeutic Cancer Vaccines Market, France, Forecast ($m), 2010-2018 Figure 13: Cancer Vaccines Market, Germany, Revenue ($m), 2006-2010 Figure 14: Prophylactic Cancer Vaccines Market, Germany, Forecast ($m), 2010-2018 Figure 15: Therapeutic Cancer Vaccines Market, Germany, Forecast ($m), 2010-2018 Figure 16: Cancer Vaccines Market, Italy, Revenue ($m), 2006-2010 Figure 17: Prophylactic Cancer Vaccines Market, Italy, Forecast ($m), 2010-2018 Figure 18: Therapeutic Cancer Vaccines Market, Italy, Forecast ($m), 2010-2018 Figure 19: Cancer Vaccines Market, Spain, Revenue ($m), 2006-2010 Figure 20: Prophylactic Cancer Vaccines Market, Spain, Forecast ($m), 2010-2018 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 21: Therapeutic Cancer Vaccines Market, Spain, Forecast ($m), 2013-2018 Figure 22: Cancer Vaccines Market, The UK, Revenue ($m), 2006-2010 Figure 23: Prophylactic Cancer Vaccines Market, The UK, Forecast ($m), 2010-2018 Figure 24: Therapeutic Cancer Vaccines Market, The UK, Forecast ($m), 2013-2018 Figure 25: Prophylactic Cancer Vaccines Market, Japan, Forecast ($m), 2010-2018 Figure 26: Therapeutic Cancer Vaccines Market, Japan, Forecast ($m), 2014-2018 Figure 27: Opportunity and Unmet Need in the Prophylactic Cancer Vaccines Market, 2011 Figure 28: Opportunity and Unmet Need in the Therapeutic Cancer Vaccines Market, 2011 Figure 29: Prophylactic Cancer Vaccines - Strategic Competitor Assessment, 2011 Figure 30: Therapeutic Cancer Vaccines - Strategic Competitor Assessment, 2011 Figure 31: Prophylactic Cancer Vaccines - Pipeline by Phases of Development, 2011 Figure 32: Therapeutic Cancer Vaccines - Pipeline by Phase of Development, 2011 Figure 33: Prophylactic Cancer Vaccines - Technology Trends Analytics Framework, 2011 Figure 34: Prophylactic Cancer Vaccines - Technology Trends Analytics Framework - Description, 2011 Figure 35: Therapeutic Cancer Vaccines- Technology Trends Analytics Framework - Description, 2011 Figure 36: Therapeutic Cancer Vaccines- Technology Trends Analytics Framework - Description, 2011 Figure 37: Prophylactic Cancer Vaccines - Pipeline by Vaccine Type, 2011 Figure 38: Therapeutic Cancer Vaccines - Pipeline by vaccine type, 2011 Figure 39: Cancer Vaccines - Clinical Trials by Country, 2011 Figure 40: Cancer Vaccines - Clinical Trials by Phase, 2011 Figure 41: Cancer Vaccines - Clinical Trials by Status, 2011 Figure 42: Cancer Vaccines - Overall Sponsors, 2011 Figure 43: Cancer Vaccines - Prominent Sponsors, 2011 Figure 44: Cancer Vaccines - Prominent Sponsors, 2011 Figure 45: Cancer Vaccines Market, Drivers and Barriers ,2011 Figure 46: Implications for Future Market Competition in the Prophylactic Cancer Vaccines Market, 2011 Figure 47: Implications for Future Market Competition in the Therapeutic Cancer Vaccines Market, 2011 Figure 48: Cancer Vaccines Market - Pipeline by Company, 2011 Figure 49: GlobalData Market Forecasting Model
Report Price: Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Licence Type
Price
$ 3500
Site Licence
$ 7000
Enterprise Wide Licence
$ 10500
Related Reports: Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019
Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Amnesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Waldenstrms Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018 Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Hepatic Encephalopathy - Pipeline Assessment and Market Forecasts to 2019 Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018 http://www.jsbmarketresearch.com/healthcare-medical/r-cancer-vaccinespipeline-assessment-and-market-forecasts-135232
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/